| Previous Close | 5.02 |
| Open | 5.02 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 4.96 - 5.05 |
| 52 Week Range | 3.66 - 6.64 |
| Volume | 138,166 |
| Avg. Volume | 173,246 |
| Market Cap | 235.23M |
| Beta | 2.17 |
| PE Ratio (TTM) | -3.50 |
| EPS (TTM) | -1.43 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.60 |
- GlobeNewswire•13 hours ago
Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference
DURHAM, N.C., Sept. 20, 2017-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief ...
- GlobeNewswire•9 days ago
Chimerix Appoints Heather Knight-Trent, PharmD, as Vice President of Regulatory Affairs
DURHAM, N.C., Sept. 12, 2017-- Chimerix, a biopharmaceutical company committed to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced ...
- Capital Cube•20 days ago
ETFs with exposure to Chimerix, Inc. : August 31, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Chimerix, Inc. Here are 5 ETFs with the largest exposure to CMRX-US. Comparing the performance and risk of Chimerix, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
